GleamWall
中文EN

SYRE Spyre Therapeutics, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1636282 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-77.1%
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-35.0%
ROA-32.9%
ROIC (approx.)-29.1%
Asset turnover—

Leverage & solvency

Liabilities / assets4.4%
Debt / equity0.00x
Current ratio27.40x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.94x
Accruals ratio-1.8%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue———————$0
R&D expense$89.17M$65.50M$60.41M$44.64M$45.25M$40.15M$41.62M$50.48M
SG&A expense$16.55M$16.14M$15.23M$12.53M$11.64M$11.79M$11.94M$10.77M
Operating income-$105.72M-$41.64M-$45.64M-$57.17M-$56.89M-$41.94M-$53.57M-$61.25M
Pretax income-$96.12M-$36.20M-$69.00M-$62.53M-$11.18M-$36.72M-$44.79M-$56.30M
Income tax$0$0$0$0$0$0-$15,000$1,000
Net income-$96.12M-$36.20M-$69.00M-$62.53M-$11.18M-$36.72M-$44.77M-$56.30M
EBITDA———————-$61.25M
EPS (diluted)——-0.74—————
Balance sheet
Cash & equivalents$82.73M$162.01M$97.19M$85.72M$64.90M$81.66M$48.49M$89.42M
Short-term investments$989.18M$983.34M$644.28M$670.81M$421.30M$444.92M$516.33M$513.66M
Current assets$1.10B$1.17B$763.95M$777.78M$504.60M$538.83M$569.77M$608.47M
Total assets$1.10B$1.17B$763.95M$777.78M$504.60M$538.83M$569.78M$608.48M
Current liabilities$40.14M$63.30M$85.16M$58.69M$46.27M$83.06M$70.68M$54.06M
Total liabilities$48.19M$71.86M$93.14M$62.55M$49.50M$83.06M$87.17M$90.68M
Shareholders' equity$1.05B$1.10B$670.81M$715.24M$455.10M$455.77M$482.61M$517.80M
Shares outstanding89.95M88.06M78.84M78.19M60.47M60.37M60.28M60.26M
Cash flow statement
Operating cash flow-$77.50M-$69.88M-$57.37M-$44.58M-$37.12M-$46.56M-$40.99M-$37.20M
Investing cash flow-$3.80M-$297.90M$56.58M-$247.41M$25.00M$79.00M-$61,000-$170.54M
Financing cash flow$2.02M$432.60M$12.26M$312.81M-$4.64M$731,000$125,000$225.60M
Depreciation & amortization———————$0
Stock-based compensation$14.17M$13.51M$12.81M$9.81M$9.57M$9.38M$8.86M$9.22M

Free plan shows the latest 8 periods; Pro shows all 47 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.